Proteomics technologies for biomarker discovery in multiple sclerosis

Vaibhav Singh; Rogier Hintzen; Theo Luider; Marcel Stoop

doi:10.1016/j.jneuroim.2011.11.004

Proteomics technologies for biomarker discovery in multiple sclerosis

Vaibhav Singh, Rogier Hintzen, Theo Luider, Marcel Stoop

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

18 Citations (Scopus)

Abstract

Multiple sclerosis is a disabling inflammatory and neurodegenerative disorder that predominantly affects young adults. There is a great need for biomarkers, which could elucidate pathology as well as provide prognosis of disease progression and therapy response in multiple sclerosis. Rapidly evolving, technology driven applications such as mass spectrometry based proteomics are currently being developed for this purpose. In this review, we will outline the current status of the field and detail a number of the bottlenecks as well as future prospects of this type of biomarker research. (C) 2011 Elsevier B.V. All rights reserved.

Original language	Undefined/Unknown
Pages (from-to)	40-47
Number of pages	8
Journal	Journal of Neuroimmunology
Volume	248
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2011.11.004
Publication status	Published - 2012

Research programs

EMC MM-03-44-06
EMC MM-04-44-02

Access to Document

10.1016/j.jneuroim.2011.11.004

http://hdl.handle.net/1765/33592

Cite this

@article{d1b70c3b6d4f485d95d3b0e6793e4735,

title = "Proteomics technologies for biomarker discovery in multiple sclerosis",

abstract = "Multiple sclerosis is a disabling inflammatory and neurodegenerative disorder that predominantly affects young adults. There is a great need for biomarkers, which could elucidate pathology as well as provide prognosis of disease progression and therapy response in multiple sclerosis. Rapidly evolving, technology driven applications such as mass spectrometry based proteomics are currently being developed for this purpose. In this review, we will outline the current status of the field and detail a number of the bottlenecks as well as future prospects of this type of biomarker research. (C) 2011 Elsevier B.V. All rights reserved.",

author = "Vaibhav Singh and Rogier Hintzen and Theo Luider and Marcel Stoop",

year = "2012",

doi = "10.1016/j.jneuroim.2011.11.004",

language = "Undefined/Unknown",

volume = "248",

pages = "40--47",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Proteomics technologies for biomarker discovery in multiple sclerosis

AU - Singh, Vaibhav

AU - Hintzen, Rogier

AU - Luider, Theo

AU - Stoop, Marcel

PY - 2012

Y1 - 2012

N2 - Multiple sclerosis is a disabling inflammatory and neurodegenerative disorder that predominantly affects young adults. There is a great need for biomarkers, which could elucidate pathology as well as provide prognosis of disease progression and therapy response in multiple sclerosis. Rapidly evolving, technology driven applications such as mass spectrometry based proteomics are currently being developed for this purpose. In this review, we will outline the current status of the field and detail a number of the bottlenecks as well as future prospects of this type of biomarker research. (C) 2011 Elsevier B.V. All rights reserved.

AB - Multiple sclerosis is a disabling inflammatory and neurodegenerative disorder that predominantly affects young adults. There is a great need for biomarkers, which could elucidate pathology as well as provide prognosis of disease progression and therapy response in multiple sclerosis. Rapidly evolving, technology driven applications such as mass spectrometry based proteomics are currently being developed for this purpose. In this review, we will outline the current status of the field and detail a number of the bottlenecks as well as future prospects of this type of biomarker research. (C) 2011 Elsevier B.V. All rights reserved.

U2 - 10.1016/j.jneuroim.2011.11.004

DO - 10.1016/j.jneuroim.2011.11.004

M3 - Article

C2 - 22129845

SN - 0165-5728

VL - 248

SP - 40

EP - 47

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -